JP2022515373A5 - - Google Patents

Info

Publication number
JP2022515373A5
JP2022515373A5 JP2021534632A JP2021534632A JP2022515373A5 JP 2022515373 A5 JP2022515373 A5 JP 2022515373A5 JP 2021534632 A JP2021534632 A JP 2021534632A JP 2021534632 A JP2021534632 A JP 2021534632A JP 2022515373 A5 JP2022515373 A5 JP 2022515373A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
composition according
disease
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534632A
Other languages
English (en)
Japanese (ja)
Other versions
JP7515480B2 (ja
JP2022515373A (ja
Filing date
Publication date
Priority claimed from EP18306716.4A external-priority patent/EP3669876A1/en
Application filed filed Critical
Publication of JP2022515373A publication Critical patent/JP2022515373A/ja
Publication of JP2022515373A5 publication Critical patent/JP2022515373A5/ja
Application granted granted Critical
Publication of JP7515480B2 publication Critical patent/JP7515480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534632A 2018-12-18 2019-12-18 認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン Active JP7515480B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306716.4 2018-12-18
EP18306716.4A EP3669876A1 (en) 2018-12-18 2018-12-18 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
PCT/EP2019/085927 WO2020127468A1 (en) 2018-12-18 2019-12-18 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS

Publications (3)

Publication Number Publication Date
JP2022515373A JP2022515373A (ja) 2022-02-18
JP2022515373A5 true JP2022515373A5 (cg-RX-API-DMAC7.html) 2022-12-26
JP7515480B2 JP7515480B2 (ja) 2024-07-12

Family

ID=65278139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534632A Active JP7515480B2 (ja) 2018-12-18 2019-12-18 認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン

Country Status (26)

Country Link
US (1) US12583884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3669876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7515480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102845328B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260366B (cg-RX-API-DMAC7.html)
AU (1) AU2019409912B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118210C (cg-RX-API-DMAC7.html)
CL (1) CL2021001458A1 (cg-RX-API-DMAC7.html)
DK (1) DK3897655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987823T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068626T2 (cg-RX-API-DMAC7.html)
IL (1) IL284032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897655T (cg-RX-API-DMAC7.html)
MA (1) MA54518B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897655T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006904A (cg-RX-API-DMAC7.html)
PL (1) PL3897655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897655T (cg-RX-API-DMAC7.html)
RS (1) RS66013B1 (cg-RX-API-DMAC7.html)
SI (1) SI3897655T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020127468A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103284B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
WO2024085245A1 (ja) 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
CN101790521A (zh) 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) * 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
LT2976074T (lt) * 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
IL276697B2 (en) 2018-02-20 2024-08-01 Aelis Farma 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders

Similar Documents

Publication Publication Date Title
JP2022515293A5 (cg-RX-API-DMAC7.html)
JP2020504156A5 (cg-RX-API-DMAC7.html)
JP2017531020A5 (cg-RX-API-DMAC7.html)
JP2022549335A5 (cg-RX-API-DMAC7.html)
ES2634204T3 (es) Composición farmacéutica que comprende derivados de piridona
JP2022539152A5 (cg-RX-API-DMAC7.html)
JPWO2020138491A5 (cg-RX-API-DMAC7.html)
JP2015525766A (ja) 神経変性障害を治療するためのテトラサイクリン化合物
CN103732594A (zh) 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
JP2022519744A5 (cg-RX-API-DMAC7.html)
JP2019532968A5 (cg-RX-API-DMAC7.html)
JP2011516588A5 (cg-RX-API-DMAC7.html)
JP2005508381A5 (cg-RX-API-DMAC7.html)
RU2021117520A (ru) 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ
JPWO2021153665A5 (cg-RX-API-DMAC7.html)
Lim et al. A case of Stevens-Johnson syndrome probably induced by herbal medicine
JP2025506201A5 (cg-RX-API-DMAC7.html)
BRPI0407140A (pt) Droga terapêutica para vìrus
PT1656458E (pt) Gene humano de susceptibilidade ao autismo e suas utilizações
Lanzenberger et al. Sex differences in neurology and psychiatry
RU2222327C2 (ru) Способ получения лекарственного препарата
CN106946701B (zh) 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用
FI3909568T3 (fi) Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin
Younger Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders
JP2024511945A5 (cg-RX-API-DMAC7.html)